0001209191-21-046028.txt : 20210708 0001209191-21-046028.hdr.sgml : 20210708 20210708181557 ACCESSION NUMBER: 0001209191-21-046028 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210706 FILED AS OF DATE: 20210708 DATE AS OF CHANGE: 20210708 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hardie Robert D. CENTRAL INDEX KEY: 0001804350 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40551 FILM NUMBER: 211081202 MAIL ADDRESS: STREET 1: 210 RIDGE MCINTIRE ROAD, SUITE 350 CITY: CHARLOTTESVILLE STATE: VA ZIP: 22903 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Acumen Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001576885 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 364108129 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4435 NORTH FIRST STREET, SUITE 360 CITY: LIVERMORE STATE: CA ZIP: 94551 BUSINESS PHONE: 925-368-8508 MAIL ADDRESS: STREET 1: 4435 NORTH FIRST STREET, SUITE 360 CITY: LIVERMORE STATE: CA ZIP: 94551 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-07-06 1 0001576885 Acumen Pharmaceuticals, Inc. ABOS 0001804350 Hardie Robert D. C/O ACUMEN PHARMACEUTICALS, INC. 427 PARK STREET CHARLOTTESVILLE VA 22902 0 0 1 0 Common Stock 2021-07-06 4 C 0 2950484 A 3040193 I See footnote Common Stock 2021-07-06 4 P 0 312500 16.00 A 3352693 I See footnote Common Stock 2021-07-06 4 C 0 657985 A 657985 I See footnote Series A-1 Preferred Stock 2021-07-06 4 C 0 1634515 0.00 D Common Stock 1634515 0 I See footnote Series B Preferred Stock 2021-07-06 4 C 0 1315969 0.00 D Common Stock 1315969 0 I See footnote Series B Preferred Stock 2021-07-06 4 C 0 657985 0.00 D Common Stock 657985 0 I See footnote On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. /s/ Katherine Denby, Attorney-in-Fact 2021-07-08